Your browser does not support iframes.
Auxilium Pharmaceuticals Inc. (Nasdaq: AUXL) reported positive results from two late stage clinical trials of its Peyronie's disease treatment Xiaflex sending the stock price soaring $3.06 to close at $21.91.